CNTXT
16.11.2023 11:01:35 CET | Business Wire | Press release
Following yesterday's successful launch of Google Cloud's new region in the Kingdom of Saudi Arabia, CNTXT has been appointed as Google Cloud’s exclusive reseller for local organizations and multinationals purchasing Google Cloud Platform Services on a standalone basis through their Saudi-based entities.
Underpinned by a robust collaboration between CNTXT and Google Cloud in the Kingdom, CNTXT will also support Google Cloud partners in the Kingdom to deliver cloud professional and managed services. One of the key focus areas for CNTXT will be accelerating the journey of local Saudi-based independent software vendors (ISVs) to the cloud and the Google Cloud Marketplace, fostering more software development and deployment.
Additionally, CNTXT is offering support for workloads hosted in the Kingdom of Saudi Arabia through its strategic collaboration with the Saudi Information Technology Company (SITE) and Fortanix. This landmark partnership is designed to provide Google Cloud customers with security solutions leveraging the new in-country Google Cloud region.
Google Cloud is the new way to cloud, and shared fate is the new way to operate, manage risk, and succeed in shared responsibility. This initiative underscores Google Cloud and CNTXT's joint commitment to delivering solutions that help Saudi businesses meet data security and compliance requirements for enterprises.
Established last year as a joint venture between Aramco and Cognite, CNTXT has evolved into a leading digital transformation company headquartered in Riyadh. This partnership with Google Cloud further solidifies CNTXT’s commitment to leading the digital transformation change in the Kingdom.
Nabil Al-Nuaim, Aramco Senior Vice President of Digital & Information Technology, stated: “When it comes to spearheading the digital transformation across the Kingdom’s public and private sectors, CNTXT plays a significant and pivotal role in collaboration with its esteemed partners, which is undeniably of paramount importance. Their unwavering dedication to empower and upskill local talent aligns seamlessly with our visionary pursuit of a digitally empowered Saudi Arabia. This marks the beginning of a transformative era, a magnificent milestone in the Kingdom's digital landscape that leads to unprecedented progress and endless possibilities."
Abdul Rahman Al Thehaiban, Managing Director, Middle East, Turkey and Africa, Google Cloud, said: "Google Cloud stands as one of the pioneering hyperscalers to launch a cloud region in the Kingdom of Saudi Arabia, a clear manifestation of our commitment to leading the digital evolution of the region.”
Bader Al Madi, Saudi Arabia Country Manager, Google Cloud, said: “Our partnership with CNTXT will support Google Cloud’s plans to empower every business and every person with access to the latest cloud technologies in the Kingdom of Saudi Arabia. We look forward to working hand in hand with CNTXT together with all our partners to pave the path for the Kingdom’s digital transformation and collaborate on helping businesses of all sizes in the country accelerate their digital transformation, optimize their operations, reduce costs and deliver exceptional customer experiences.”
CNTXT CEO, Abdullah Jarwan, remarked, "We are honored to become a leading cloud and digital transformation company in the Kingdom. Our collaboration with Google Cloud will empower us to work on accelerating the digital transformation of public and private sectors in Saudi Arabia. We are committed to building a brighter, more technologically advanced future for the Kingdom."
About CNTXT: CNTXT, a joint venture between Saudi Aramco and Cognite, is a leading digital transformation company headquartered in Riyadh, Saudi Arabia. With a mission to empower organizations through technology and innovation, CNTXT leverages strategic partnerships and a network of resellers to accelerate digital transformation across public and private sectors in the Kingdom.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116735194/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom